PPIDT00114

Drug Information
NameInsulin glulisine
SequenceGIVEQCCTSICSLYQLENYCN
DrugBank_IDDB01309
Typebiotech
IndicationInsulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Dosage Forms
Form Route Strength
Injection, solution Intravenous; Subcutaneous
100 Units/ml
Injection, solution Intravenous; Subcutaneous
100 [iU]/1mL
Injection, solution Parenteral; Subcutaneous
100 U/ML
Solution Subcutaneous
100 unit / mL
Solution Intravenous; Subcutaneous
10000000 IU
Solution Subcutaneous
100 IU
Injection, solution Subcutaneous
100 U/ML
Injection, solution Subcutaneous
3.49 mg
Injection Subcutaneous
100 U/ml
Injection, solution Subcutaneous
100 [iU]/1mL
Injection, solution Subcutaneous
100 Units/mL
Solution Subcutaneous
100 iu/1ml
Solution Parenteral
100.000 UI
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P06213 INSR Insulin receptor Homo sapiens agonist Link
target P08069 IGF1R Insulin-like growth factor 1 receptor Homo sapiens activator Link
enzyme P05177 CYP1A2 Cytochrome P450 1A2 Homo sapiens inducer Link